Ken J Ishii Selected Research

Peptides (Polypeptides)

12/2023	TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
1/2023	Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile.
1/2021	S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
12/2015	Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
9/2015	[Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
2/2009	A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken J Ishii Research Topics

Disease

39	Infections 12/2023 - 07/2002
37	Neoplasms (Cancer) 01/2024 - 12/2003
18	Inflammation (Inflammations) 03/2024 - 08/2002
18	Malaria 01/2022 - 07/2002
17	Bites and Stings (Sting) 01/2024 - 12/2011
16	Human Influenza (Influenza) 01/2022 - 07/2006
13	Communicable Diseases (Infectious Diseases) 10/2023 - 04/2004
8	Virus Diseases (Viral Diseases) 12/2022 - 10/2005
7	Pneumonia (Pneumonitis) 12/2019 - 10/2004
6	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2005
5	Melanoma (Melanoma, Malignant) 12/2023 - 05/2006
5	Hypersensitivity (Allergy) 01/2017 - 06/2010
3	Atopic Dermatitis (Atopic Eczema) 01/2023 - 06/2015
2	Lung Neoplasms (Lung Cancer) 01/2024 - 07/2022
2	Immune System Diseases (Immune Disorders) 01/2023 - 01/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 08/2016
2	Coinfection 11/2019 - 02/2011
2	Porcine Reproductive and Respiratory Syndrome (PRRS) 11/2019 - 09/2008
2	Asthma (Bronchial Asthma) 01/2019 - 04/2013
2	Contact Dermatitis (Eczema, Contact) 01/2018 - 11/2014
2	Bacterial Infections (Bacterial Infection) 01/2017 - 02/2011
2	Ischemia 12/2015 - 07/2013
2	Lymphoma (Lymphomas) 04/2015 - 04/2014
2	Parasitemia 09/2010 - 01/2007
2	Cerebral Malaria 03/2010 - 01/2007

Drug/Important Bio-Agent (IBA)

43	VaccinesIBA 12/2023 - 01/2004
26	AntigensIBA 12/2023 - 07/2006
17	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 08/2002
16	OligodeoxyribonucleotidesIBA 12/2023 - 08/2002
13	CytokinesIBA 01/2023 - 05/2004
12	CPG-oligonucleotideIBA 07/2022 - 12/2003
11	Vaccine AdjuvantsIBA 01/2023 - 04/2004
10	InterferonsIBA 01/2024 - 10/2005
9	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 10/2004
9	Interferon Type IIBA 01/2019 - 07/2006
8	LigandsIBA 01/2022 - 04/2014
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2006
8	Nucleic AcidsIBA 01/2018 - 11/2005
7	AntibodiesIBA 01/2022 - 01/2011
7	hemozoinIBA 06/2017 - 07/2002
6	Peptides (Polypeptides)IBA 12/2023 - 02/2009
6	K3-SPGIBA 06/2023 - 08/2016
6	Interleukin-33IBA 10/2020 - 02/2012
6	Immunoglobulin G (IgG)IBA 01/2019 - 09/2010
5	Hemagglutinins (Hemagglutinin)IBA 11/2019 - 03/2015
5	cyclic guanosine monophosphate-adenosine monophosphateIBA 11/2019 - 04/2015
4	Cancer VaccinesIBA 01/2023 - 09/2015
4	InflammasomesIBA 01/2020 - 03/2010
4	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2006
4	AllergensIBA 01/2017 - 02/2004
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2016 - 05/2006
4	DNA VaccinesIBA 07/2013 - 07/2006
3	Therapeutic UsesIBA 01/2024 - 02/2004
3	Messenger RNA (mRNA)IBA 07/2023 - 01/2020
3	CyclodextrinsIBA 07/2023 - 03/2015
3	aluminum sulfate (alum)IBA 01/2023 - 01/2016
3	Interleukin-12 (IL 12)IBA 01/2022 - 04/2015
3	Toll-Like Receptor 9IBA 01/2022 - 08/2005
3	Pattern Recognition ReceptorsIBA 11/2019 - 09/2008
3	Immunoglobulin E (IgE)IBA 01/2019 - 06/2015
3	Phosphotransferases (Kinase)IBA 07/2016 - 12/2011
3	RNA (Ribonucleic Acid)IBA 03/2015 - 05/2006
3	AluminumIBA 01/2013 - 09/2010
2	IntegrinsIBA 03/2024 - 11/2014
2	vadimezanIBA 01/2024 - 01/2013
2	Malaria VaccinesIBA 12/2023 - 01/2013
2	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2021
2	cyclic diadenosine phosphateIBA 12/2023 - 11/2019
2	PolymersIBA 07/2023 - 01/2005
2	Sizofiran (Schizophyllan)IBA 06/2023 - 01/2022
2	N-(2-cyanoethylene)urea (BA 1)IBA 10/2022 - 01/2022
2	N-methyl-valyl-amiclenomycin (BA 2)IBA 10/2022 - 01/2022
2	Phosphates (Orthophosphate)IBA 07/2022 - 05/2009
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2022 - 01/2017
2	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2022 - 01/2017
2	Carrier Proteins (Binding Protein)IBA 01/2020 - 02/2014
2	EpitopesIBA 01/2019 - 02/2017
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2019 - 01/2016
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 01/2018
2	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2018 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2014
2	Poly I-CIBA 01/2018 - 02/2011
2	Interleukin-17 (Interleukin 17)IBA 01/2018 - 01/2018
2	Interleukin-23 (Interleukin 23)IBA 01/2018 - 01/2018
2	Hemoglobins (Hemoglobin)IBA 06/2017 - 01/2005
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 04/2015
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017 - 03/2010
2	Neoplasm Antigens (Tumor Antigens)IBA 08/2016 - 09/2015
2	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 12/2015 - 02/2014
2	Toll-Like Receptor 4IBA 12/2015 - 07/2013
2	Retinaldehyde (Retinal)IBA 12/2015 - 07/2013
2	B-Form DNA (B-DNA)IBA 04/2015 - 01/2006
2	Hydroxyl RadicalIBA 01/2013 - 09/2010
2	Interleukin-13IBA 02/2012 - 12/2003
2	A-Form DNA (A-DNA)IBA 12/2011 - 07/2006
2	Heme (Haem)IBA 01/2010 - 01/2005

Therapy/Procedure

12	Therapeutics 10/2023 - 12/2003
11	Immunotherapy 12/2023 - 12/2003
2	Intravenous Injections 01/2022 - 08/2016
2	Intranasal Administration 01/2020 - 02/2011